Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2/Phase 3
LaMB
A Double Blind Randomised Study of Lapatinib and Placebo in Metastatic TCC of the Urothelium
- NCT00949455 ↗
- Unknown
- Queen Mary University of London
- Focused
We haven't built an HCP commentary report on LaMB (lapatinib in HER1 and/or HER2 overexpressing advanced bladder cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on LaMB so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase II/III, Randomised, Two-Arm, Comparison of Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With HER1 and/or HER2 Overexpressing Locally Advanced or Metastatic Bladder Cancer [LaMB]
- Phase
- Phase 2/Phase 3
- Status
- Unknown
- Conditions
- Bladder Cancer
- Interventions
- lapatinib ditosylate; Placebo
- Arms
- Arm I · Experimental
- Arm II · Placebo comparator
- Enrollment
- 204 (estimated)
- Primary outcomes
- Progression free survival
- Sponsor
- Queen Mary University of London with GlaxoSmithKline
- Start
- Mar 2009
- Primary completion
- Jul 2015 (estimated)
- Results posted
- No
- Registry record
- NCT00949455 · updated Apr 15, 2015
Publications
linked from the registry- Bellmunt J, Werner L, Bamias A, Fay AP, Park RS, Riester M, Selvarajah S, Barletta JA, Berman DM, de Muga S, Salido M, Gallardo E, Rojo F, Guancial EA, Bambury R, Mullane SA, Choueiri TK, Loda M, Stack E, Rosenberg J. HER2 as a target in invasive urothelial carcinoma. Cancer Med. 2015 Jun;4(6):844-52. doi: 10.1002/cam4.432. Epub 2015 Feb 26. PubMed 25720673